Search research articles
Contact Us
Filters
Showing results (51-60 of 273) with videos related to
Page
of 28
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 23, 2009
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
Vincent T Ho, Julie Aldridge, Haesook T Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 1, 2013
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation
Gita Thanarajasingam, Haesook T Kim, Corey Cutler, et al.
Blood Advances
|
July 16, 2025
Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma
Philippe Armand, Pier Luigi Zinzani, John M Timmerman, et al.
Leukemia & Lymphoma
|
July 22, 2024
A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma
Eric Jacobsen, Ashley Plant, Robert Redd, et al.
Haematologica
|
July 2, 2026
Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma
Joseph G Schroers-Martin, Reid Merryman, Michael A Spinner, et al.
Blood
|
November 8, 2019
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative
Sanjay S Patel, Jason L Weirather, Mikel Lipschitz, et al.
Blood
|
May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 27, 2007
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation
Philippe Armand, Haesook T Kim, Corey S Cutler, et al.
Transplantation and Cellular Therapy
|
March 5, 2025
Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab Therapy
John Kuruvilla, Philippe Armand, Alex F Herrera, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 16, 2010
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age
John Koreth, Julie Aldridge, Haesook T Kim, et al.
Page
of 28
Search research articles
Search
Showing results (51-60 of 273) with videos related to
Sort By:
Page
of 28
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 23, 2009
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
Vincent T Ho, Julie Aldridge, Haesook T Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 1, 2013
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation
Gita Thanarajasingam, Haesook T Kim, Corey Cutler, et al.
Blood Advances
|
July 16, 2025
Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma
Philippe Armand, Pier Luigi Zinzani, John M Timmerman, et al.
Leukemia & Lymphoma
|
July 22, 2024
A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treatment of follicular lymphoma
Eric Jacobsen, Ashley Plant, Robert Redd, et al.
Haematologica
|
July 2, 2026
Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma
Joseph G Schroers-Martin, Reid Merryman, Michael A Spinner, et al.
Blood
|
November 8, 2019
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative
Sanjay S Patel, Jason L Weirather, Mikel Lipschitz, et al.
Blood
|
May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 27, 2007
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation
Philippe Armand, Haesook T Kim, Corey S Cutler, et al.
Transplantation and Cellular Therapy
|
March 5, 2025
Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab Therapy
John Kuruvilla, Philippe Armand, Alex F Herrera, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 16, 2010
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age
John Koreth, Julie Aldridge, Haesook T Kim, et al.
Page
of 28